Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A

BACKGROUND: Hemophilia A (HA) can result in bleeding events because of low or absent clotting factor VIII (FVIII). Prophylactic treatment for severe HA includes replacement FVIII infusions and emicizumab, a bispecific factor IXa- and factor X-directed antibody. OBJECTIVE: To develop an economic mode...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Zheng-Yi, Raimundo, Karina, Patel, Anisha M., Han, Simeng, Ji, Yusi, Fang, Honghao, Zhong, Jia, Betts, Keith A., Mahajerin, Arash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391239/
https://www.ncbi.nlm.nih.gov/pubmed/32452276
http://dx.doi.org/10.18553/jmcp.2020.19406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391239/
https://www.ncbi.nlm.nih.gov/pubmed/32452276
http://dx.doi.org/10.18553/jmcp.2020.19406

Ejemplares similares